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Metabolic homeostasis requires integration of multiple signals and cellular activities. Without this
integration, conditions of obesity and diabetes often develop. Recent in vivo studies explore the
molecular basis for metabolic homestasis, showing that p62 links autophagy and mTORC1 activa-
tion to regulate adipogenesis and energy control.To confer specificity and plasticity to signal transduction cas-
cades, adaptor proteins act as hubs or nodes, organizing and
connecting myriad cellular processes. One example of such
a signal-organizing hub is the protein known as p62, or seques-
tosome1. p62 was initially identified by its ability to interact with
the atypical protein kinase C proteins (aPKCs) but was later
found to bind a relatively long list of critical signaling intermedi-
ates (Figure 1A) (Moscat and Diaz-Meco, 2009). For example, it
associates with TRAF6, regulating NF-kB signaling during osteo-
clastogenesis and bone homeostasis, and it interacts with cas-
pase-8 via its UBA domain (Moscat and Diaz-Meco, 2009).
This interaction efficiently activates the extrinsic apoptotic
pathway, which is required during TRAIL-induced cell death.
With its UBA domain, p62 also binds polyubiquitinated proteins
destined for degradation through autophagy (Moscat and Diaz-
Meco, 2009). For this activity, p62 must recruit LC3, a critical
component of the autophagic machinery (Moscat and Diaz-
Meco, 2009). By associating with a wide variety of proteins,
p62 fulfills two distinct biochemical roles: it is a signaling orga-
nizer that regulates essential cellular functions, and it is also
involved in the cellular quality-control mechanisms underlying
the disposal of misfolded proteins (Moscat and Diaz-Meco,
2009).
p62 and the Control of Metabolic Homeostasis
and Inflammation
As a signaling hub, p62 coordinates the processes required for
metabolic homeostasis. It does this, in part, through its connec-
tions with autophagy. Importantly, p62 not only binds proteins
destined for disposal by autophagy, it also gets constitutively
degraded by autophagy. This has important functional repercus-
sions in vivo. For example, genetic inhibition of autophagy in the
liver leads to poorly characterized hepatotoxicity and p62 accu-
mulation. This phenotype is rescued by the genetic inactivation
of p62 (Komatsu et al., 2007). Moreover, chronic increases in
p62 levels cause liver cell damage, which, over time, leads to
hepatocarcinogenesis (Inami et al., 2011; Takamura et al.,
2011). In this context, p62 promotes tumorigenesis by activating
two ROS scavenger systems, NRF2 and NF-kB, which reduce
oxidation-induced tumor cell death and promote cancer cell
survival and proliferation (Moscat and Diaz-Meco, 2009). These724 Cell 147, November 11, 2011 ª2011 Elsevier Inc.results illustrate that context-specific overproduction of p62
has important functional repercussions in vivo, but what is the
physiological role of p62? Recent analyses of p62-deficient
mice provide insight into this key question. Interestingly, the
loss of p62 at an organismal level resulted inmature-onset insulin
resistance and obesity (Rodriguez et al., 2006). These unex-
pected findings suggest a role for p62 in the control of metabolic
homeostasis. Consistent with this, p62-deficient mice exhibit
reduced energy expenditure and thermogenesis, along with
decreased levels of transcripts involved in these processes (Ro-
driguez et al., 2006). In addition, young mice that lack p62 func-
tion exhibit increased levels of the adipogenic master regulatory
gene PPARg in white adipose tissue long before obesity or
increased adiposity are apparent (Rodriguez et al., 2006). These
results indicate that the loss of p62 recapitulates all the charac-
teristics of metabolic syndrome, including glucose intolerance,
insulin resistance, and systemic and adipose tissue-specific
inflammation.
Interestingly, p62 deficiency leads to obesity independently of
its interaction with aPKCs (Lee et al., 2010). For example, PKCz
null mice do not exhibit obesity, although they are more prone to
insulin resistance and glucose intolerance. These symptoms
stem from increased production of inflammatory cytokines not
by immune cells but by the mutant adipocytes (Lee et al.,
2010). These observations indicate that the p62-PKCz cassette
controls two key aspects of physiology, which directly impinge
on metabolic syndrome. p62 normally represses obesity and
enhances energy expenditure, whereas PKCz represses the
proinflammatory actions of obesity. Consistent with this notion,
PKCz/IL-6 double-knockout mice exhibit normal glucose toler-
ance and insulin responses, along with reduced hepatosteato-
sis, even when fed a high-fat diet (Lee et al., 2010). Conse-
quently, both signaling proteins may play positive roles in
preventing metabolic syndrome and type 2 diabetes.
Much evidence suggests that p62 represses adiposity in an
ERK1-dependent cell-autonomous manner (Rodriguez et al.,
2006). Embryo fibroblasts from p62-deficient mice and 3T3-L1
cells lacking p62 display high levels of activated ERK concomi-
tant with enhanced adipogenesis (Rodriguez et al., 2006). p62
interacts preferentially with ERK1 over ERK2, and the reduction
of ERK1, but not of ERK2, completely reverses adipogenesis in
Figure 1. Role of p62 in Autophagy and
mTORC1 Regulation
(A) Domain organization and interacting partners
of p62. PB1, Phox/Bem domain 1, interacts with
ERK1 to control adipogenesis and, with aPKCs, to
control NF-kB; the interaction with NBR1 is also
through the PB1, but its role needs to be clarified.
ZZ, atypical zinc finger, governs the interaction
with RIP andmight be relevant for TNF-a-activated
NF-kB. TB, TRAF6 binding, accounts for p62’s
role in IL-1, NGF, and RANK toward NF-kB. LIR,
LC3-interacting region, locates p62 in the auto-
phagosomes; KIR, Keap-interacting region, serves
to regulate NRF2 activation; UBA, ubiquitin-asso-
ciated, mediates the interaction with polyubi-
quitinated proteins, including caspase-8, and
modulates TRAF6 interaction and activity.
(B) p62 senses nutrient signals and activates
mTORC1, inhibiting autophagy and creating a loop
that results in enhanced p62 levels.
(C) During senescence and lysosomal biogenesis,
p62 and mTORC1 are most likely separated from
the autophagosome, which generates amino acids
that can, in turn, regulate mTORC1 activation.
(D) High-calorie diets promote lipogenesis and
adiposity through mTORC1 activation, which is
antagonized by p62. p62, itself, is modulated
by autophagy, and that likely controls the anti-
inflammatory actions of PKCz.cultured cells. Importantly, this phenomenon is recapitulated
in vivo with p62/ERK1 double-knockout mice displaying normal
adipogenesis and adiposity and no obesity, hepatosteatosis, or
insulin resistance (Moscat and Diaz-Meco, 2009).
Altogether, these data suggest that p62’s associations with
ERK1 and PKCz differentially regulate metabolic homeostasis.
The p62-ERK1 pair regulates mature-onset obesity and type 2
diabetes, whereas the p62-PKCz pair regulates obesity-induced
inflammation and type 2 diabetes. According to this model,
decreased p62 expression emerges as a risk factor for obesity
and type 2 diabetes. As obesity and glucose intolerance are
often associated with aging, it is tempting to speculate that
reduced levels of p62 might constitute a risk factor for the alter-
ations in metabolic homeostasis that go hand-in-hand with the
aging process.
Compartmentalization of mTORC1 and Autophagy
Recent data demonstrate that p62 impinges on another critical
regulator of metabolic homeostasis: the primary nutrient-
sensing complex, mTORC1. The core components of mTORC1
include the mTOR kinase, raptor, and mLST8/GbL (Guertin and
Sabatini, 2007). Recent results have begun to shed light on the
upstream mechanisms that connect mTORC1 to nutrient avail-
ability and couple its response to the lysosomal compartment
(Sancak et al., 2010). Heterodimers of GTP-bound RagA/B
bind raptor and direct mTORC1 to the lysosomal surface where
it can interact with its activator, Rheb (Sancak et al., 2010). An
unbiased proteomic analysis identified raptor as a p62-interact-
ing protein (Duran et al., 2011). The p62-raptor interaction
explains why cells require p62 to activate mTORC1 in response
to cell stimulation by amino acids (Duran et al., 2011). Without
p62 function, autophagy is upregulated in mammalian cellsand in C. elegans, similar to the upregulation of autophagy that
accompanies decreased mTORC1 activity (Duran et al., 2011).
This unexpected finding implies that p62, which is degraded
by autophagy, also regulates autophagy, creating a feedforward
loop by which p62 activation of mTORC1 results in higher p62
levels. These increased levels of p62 thereby promote even
more mTORC1 activity (Figure 1B). The physiological signifi-
cance of this loop is not completely clear, but it suggests that
when amino acids levels are low, mTORC1 activity is reduced
and autophagy is upregulated. Moreover, it suggests that the
p62-mTORC1-autophagy feedforward loop negatively regulates
mTORC1 activation during chronic nutrient deprivation. A poten-
tial role for this negative regulation could be to ensure the irre-
versibility of cell death upon nutrient starvation. Thus, we envi-
sion a model in which a prolonged lack of nutrients produces
chronic activation of autophagy and long-term reduction of
p62. This permanent reduction in p62 would make it impossible
for the cell to reactivate the mTORC1 pathway if nutrients
become available again (Figure 1B). According to this mecha-
nism, cells that reach a critical level of nutrient stress-induced
damage would not recover.
It is likely that p62 carries out additional roles that enable
mTORC1’s response to amino acid flux related to the intracellular
localization of mTORC1 and p62. Recent data support an
mTORC1-mediated link between autophagy and inflammatory
cytokine synthesis during oncogene-induced senescence (Narita
et al., 2011). Althoughautophagyandprotein synthesismayseem
to oppose each other, in this context they may work in concert,
with autophagy generating the amino acid building blocks
needed for mTORC1-mediated cytokine synthesis. Importantly,
ULK1, the kinase that activates autophagy, ismost likely localized
in a different compartment of the cell than mTORC1 and p62 inCell 147, November 11, 2011 ª2011 Elsevier Inc. 725
senescent cells. During senescence, p62 may interact with
mTORC1,which is localizedon theGolgi, away from the autopha-
gosomes (Figure 1C). This localization would ensure mTORC1
activation and function and, at the same time, protect its partner,
p62, from degradation by autophagy.
The p62-mTORC1 connection could also be implicated in
lysosome biogenesis following the termination of autophagy. In
this scenario, mTORC1 is reactivated during prolonged starva-
tion by the products generated by the autolysosomes (Yu
et al., 2010). This second phase of mTORC1 activation requires
p62 and the regeneration of functional lysosomes. In keeping
with this notion, recent reports demonstrate the critical role of
the transcription factor TFEB in connecting autophagy and lyso-
somal biogenesis (Settembre et al., 2011). TFEB drives the
expression of autophagy and lysosomal gene products as
well as that of p62 (Settembre et al., 2011). Although p62 is a
substrate of autophagy, it could also be a critical component
of the cellular remodeling that occurs post-autophagy. Testing
these hypotheses will yield a better understanding of p62’s role
as a critical regulator of cellular homeostasis and provide new
insight into how p62 modulates autophagy and mTORC1 activa-
tion in response to nutrient starvation and refeeding in various
physiological contexts.
Autophagy, p62, mTORC1, and Metabolic Control
The evidence that p62 acts as a cellular metabolic switch in auto-
phagy is also important on the organismal level. For instance,
p62, mTORC1, and autophagy play important roles in adipogen-
esis. When the autophagy regulator ATG7 is specifically in-
activated in adipocytes of mice, obesity and adiposity decrease,
whereas glucose tolerance and insulin sensitivity increase
(Zhang et al., 2009). Considering that inhibition of autophagy
provokes the accumulation of p62 (Zhang et al., 2009), and
that the overexpression of p62 inhibits adipogenesis (Rodriguez
et al., 2006), we hypothesize that simultaneous inactivation of
p62 and Atg7 would restore normal adipogenesis. In this regard,
it should be emphasized that the loss of p62 not only increases
adipogenesis but also results in decreased energy expenditure
and the downregulation of genes involved in energy utilization
(Rodriguez et al., 2006). In contrast, the loss of Atg7 in adipose
tissue results in increased energy expenditure as measured by
increased b-oxidation rates. Moreover, Atg7/ white adipose
tissue acquired some characteristics of brown adipocytes,
including increased mitochondrial content and multilocular lipid
droplets, key characteristics of brown adipocytes (Zhang et al.,
2009). Conversely, p62/ brown adipose tissue looks more
like white adipose tissue with a clear reduction in UCP1 mRNA
levels (Rodriguez et al., 2006). The studies described above
suggest that autophagy regulates systemic metabolic homeo-
stasis and cell-autonomous adipogenesis through p62 inhibition.
We suggest that the simple regulation of autophagy, p62 levels,
or both in adipose tissue is sufficient to influence whole-body
metabolic homeostasis. However, recent data also implicate
the brain in this process. Genetic ablation of Atg7 in agouti-
related peptide (AgRP) neurons resulted in decreased body
weight and fat mass, likely due to reduced food intake (Kaushik
et al., 2011). The mechanisms underlying this phenomenon
seem to be complex and might involve the generation of circu-726 Cell 147, November 11, 2011 ª2011 Elsevier Inc.lating free fatty acids during starvation that are taken up by orexi-
genic hypothalamic AgRP neurons that synthesize triglycerides
and activate autophagy, which in turn upregulates AgRP levels
and triggers the appropriate homeostatic response (Kaushik
et al., 2011). It is unclear how autophagy in these neurons regu-
lates the generation of AgRP, but p62 does not seem to be
involved in this process because systemic loss of p62 in mice
does not affect food intake (Rodriguez et al., 2006). Therefore,
although autophagy may be involved in the control of obesity
in more than one organ or tissue, the role of p62 seems to be
restricted to the adipose compartment.
All these recent data support a model wherein autophagy and
p62 play opposing roles in adipogenesis and obesity with adipo-
cytes functioning as key mediators of obesity-associated inflam-
mation and whole-body metabolic homeostasis. Connecting the
mTORC1 pathway with p62 and autophagy uncovers additional
complexity. In this regard, it is surprising that inhibition of
mTORC1 in adipose tissue, by genetic inactivation of raptor,
leads to a lean phenotype with resistance to high-fat-diet-
induced obesity (Polak et al., 2008). Although these results agree
with previous data demonstrating that loss of the mTORC1 tar-
get S6K1 results in an obesity-resistant phenotype (Um et al.,
2004), they are at odds with mTORC1 negatively regulating auto-
phagy and promoting adipogenesis and adiposity in vivo (Zhang
et al., 2009). These effects of mTORC1 activity seem to be tissue
specific, as the selective inactivation of raptor in muscle results
in decreased oxidative capacity and reduced mitochondrial
gene expression (Bentzinger et al., 2008), whereas raptor dele-
tion in adipocytes promotes increased energy expenditure
(Polak et al., 2008). This is consistent with experiments in
cultured cells showing that mTOR controls mitochondrial func-
tion in muscle cells by regulating the activity of PGC1a via
a raptor-mTOR-YY1 complex (Cunningham et al., 2007).
Although the actions of mTORC1 in energy homeostasis are
complex, these results suggest that adipose tissue, but not
muscle, is central to the regulation of metabolism and obesity.
Moreover, inactivation of mTORC1 in fat recapitulates the lean
phenotype of total S6K1-deficient mice, but inactivation of
mTORC1 in muscle does not produce lean mice (Polak et al.,
2008). Taken together, all these findings point to mTORC1 as
a positive modulator of adiposity and lower energy expenditure
and are in agreement with the fact that obesity, both genetic
and dietary, promotes mTORC1 activity (Um et al., 2004).
One mechanism whereby mTORC1 might activate adipogen-
esis is by regulating the expression of the key adipogenic tran-
scriptional regulator SREBP-1. One function of SREBP-1 is to
promote the synthesis of PPARg activators. Interestingly, the
selective inactivation of raptor in liver correlates with resistance
to diet-induced obesity (Peterson et al., 2011), which would
imply that permanent activation of the mTORC1 pathway should
result in hepatosteatosis as a consequence of hyperproduction
of SREBP-1. Although it is clear that mTORC1 activates the
SREBP pathways through a novel mechanism involving Lipin1
(Peterson et al., 2011), the constitutive activation of mTORC1
in liver results in protection from age- and diet-induced hepato-
steatosis, most likely due to the defective synthesis of SREBP1c
and lipogenesis (Yecies et al., 2011). These surprising re-
sults illustrate the complexity of metabolic homeostasis at an
organismal level and its regulation by specific signaling cas-
cades. A confounding factor in many analyses of the mTORC1
pathway is its crosstalk with another mTOR-associated path-
way, the mTORC2-Akt signaling cascade. For example, the
permanent activation of mTORC1 in the liver leads to a complete
shutdown of the Akt pathway, which is necessary for inactivation
of the SREBP1c repressor INSIG2 (Yecies et al., 2011). This
could explain why, under certain circumstances, inactivation of
the mTORC1 pathway gives rise to the same metabolic pheno-
type as its constitutive activation. These and other questions
are important to consider when analyzing the whole-body
phenotypes of mice with ablation of negative regulators of the
mTORC1 pathway.
Concluding Remarks and Speculations
When we survey the literature, we are left with contradictory
conclusions about the relationship between autophagy, p62,
and mTORC1 function. The most recent data upend the prevail-
ing view of mTORC1, suggesting that instead of mTORC1 acting
as an upstream negative regulator of autophagy, autophagy acts
as an upstream positive regulator of mTORC1. Some examples
of this include lysosomal biogenesis and oncogene-induced
inflammation associated with senescence. This apparent par-
adox may be explained by the distinct compartmentalization of
ULK1 and autophagy, and p62 and mTORC1 inside the cell (Fig-
ure 1C). Careful biochemical purification of different p62 com-
plexes and determination of their subcellular localization will
provide clarification of this model.
Another inconsistency is that whereas mTORC1 appears to
negatively regulate autophagy, both mTORC1 and autophagy
positively regulate lipogenesis and adiposity. A potential expla-
nation for this paradox is that a high-calorie diet induces
mTORC1, causing increased adiposity and lower energy expen-
diture, which also prevents autophagy in an mTORC1-depen-
dent manner. This type of regulation could provide a negative
feedback mechanism that would result in increased p62 levels.
High levels of p62 would inevitably lead to restriction of adipo-
genesis and increased energy expenditure (Figure 1D). In this
way, metabolic homeostasis is maintained with adipocytes and
the whole organism keeping fat content and insulin responses
in a relatively normal physiological range, despite having to
cope with excessive food intake or age-induced deregulated
metabolic homeostasis. Future studies using mice with double
deficiencies in autophagy and p62 should be helpful in rigorously
testing this hypothesis.
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